All publications of “Guilherme Fleury Perini”

5 results

Not all that shines is cancer: pulmonary cryptococcosis mimicking lymphoma in [(18)] F fluoro-2-deoxy-D-glucose positron emission tomography

Nelson Hamerschlak, Jacyr Pasternak, Jairo Wagner, Guilherme Fleury Perini

DOI: 10.1590/S1679-45082012000400018

We report of a case of pulmonary cryptococcosis mimicking lymphoma in a positron emission tomography (FDG-PET) scan. A 62-year old man with diffuse large B-cell lymphoma had complete resolution of abdominal and pulmonary lesions after three cycles of rituximab-based chemotherapy (R-CHOP). However, FDG-PET showed new pulmonary nodules, suggesting active lymphoma. Chronic inflammatory granuloma was seen in the histopathological exam, with round-shaped structures compatible with fungus, later identified as Cryptococcus neoformans on culture. The lesions disappeared after 6 weeks of fluconazole […]

Hodgkin’s disease and pregnancy: case series and proposal for treatment protocol

Carolina Kassab, Guilherme Fleury Perini, Patrícia Weinschenker Bollmann, Fabio Rodrigues Kerbauy, Nelson Hamerschlak

DOI: 10.1590/S1679-45082011RC1992

ABSTRACT The peak frequency of Hodgkin’s disease convergesmatches with women of reproductive fertility age. Currently, this disease is the fourth more diagnosed neoplasia during pregnancy. In addition, there is no consensus in the literature on how to treat pregnant women because of the risks of chemotherapy for mothers and for fetuses. We report three cases of pregnant women with Hodgkin’s disease. A review of the literature was made aiming to suggest a protocol to treat these patients.

Use of gemtuzumab ozogamycin combined with conventional chemotherapy in patients with acute myeloid leukemia

Guilherme Fleury Perini, Fabio Pires de Souza Santos, Iracema Esteves, Claudia Mac-Donald Bley do Nascimento, Morgani Rodrigues, Reijane Alves de Assis, [...]

DOI: 10.1590/S1679-45082011AO1987

ABSTRACT Objective: To analyze the outcome of patients treated with gemtuzumab ozogamycin combined with conventional therapy treated at Hospital Israelita Albert Einstein. Methods: 14 patients who had high risk features (secondary leukemia, unfavorable cytogenetics, and refractory disease) were treated with gemtuzumab ozogamycin combined with conventional therapy and their outcome was analysed by reviewing their medical records. Results: Overall response rate was 58%, with 43% achieving complete response, with a median follow-up of 11 months, event-free survival was 3 months. Eleven […]